Dr Georgia McCaughan

Dr Georgia McCaughan is a clinician-researcher in haematology with a primary focus on multiple myeloma and related plasma cell disorders. Her research spans translational, clinical, and registry-based studies, with particular interests in disease biology, treatment optimisation, and mechanisms of relapse, including cancer cell dormancy and the bone microenvironment.

Georgia graduated from Sydney Medical School at the University of Sydney with First Class Honours and the University Medal.  She has also completed a Masters in Medicine (Clinical Epidemiology).  Georgia completed her Haematology Advanced Training at Westmead Hospital and Myeloma Fellowship at St Vincent’s Hospital Sydney, prior to her appointment as a Staff Specialist at St Vincent’s Hospital in 2021.

Dr McCaughan holds leadership roles within major collaborative research groups, including Chair of the Myeloma Working Group of the Australasian Leukaemia and Lymphoma Group (ALLG) and sitting on the Steering Committee of the Australasian Myeloma Research Consortium (AMarC).  She is also a member of the Medical and Scientific Advisory Group to Myeloma Australia and a member of the International Myeloma Working Group.  She serves as Principal Investigator on multiple investigator initiated and Pharmaceutical company sponsored clinical trials.  She co-leads an investigator initiated platform trial exploring novel agents in patients with multiple myeloma typically excluded from clinical trials (NORM), a collaboration between the ALLG and the Asian Myeloma Network, and led a world leading investigator initiated clinical trial utilising Romosozumab in myeloma bone disease.

Dr McCaughan is a member of the St Vincent’s/Garvan myeloma research group with an interest in cancer cell dormancy and myeloma bone disease.  She has been instrumental in establishing the St Vincent’s/Garvan Haemato-Oncology Bone Biobank, which is biobanking samples from patients with plasma cell disorders and breast cancer to try and further define the seeds of relapse across cancer types and try to identify therapies to stop relapse.

Dr McCaughan has an extensive publication and conference presentation record, including contributions to leading international meetings such as the American Society of Hematology (ASH), European Hematology Association (EHA), and the International Myeloma Society Annual Meeting (IMS). Her work encompasses clinical trials, real-world data analyses, and patient-reported outcomes research aimed at improving treatment delivery and patient experience. She has also acted as a research supervisor for projects involving evaluation of  real world practice, registry based analyses and clinical trial projects.